Comprehensive molecular profiling of lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. An integrated transcriptome, genome, methylome and proteome analysis of over 200 lung adenocarcinomas reveals high rates of somatic mutations, 18 statistically significantly mutated genes including RIT1 and MGA, splicing changes, and alterations in MAPK and PI(3)K pathway activity. This report from The Cancer Genome Atlas Research Network presents molecular profiling of 230 resected untreated lung adenocarcinomas. Integrated analyses of transcriptome, genome, methylome and proteome collectively identify high rates of somatic mutation, significantly mutated genes including RIT1 and MGA, splicing alterations driven by somatic genomic changes, and point to as yet unidentified lesions that alter MAPK and PI(3)K pathway activity. These data establish a foundation for classification and further investigations of the leading cause of cancer death worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in PIK3CA and CTNNB1 are more frequent in advanced stage tumors compared with early stage LUADs, pointing towards functional roles in malignant progression and metastasis, whereas alterations in TP53 (62.5%), RB1 (9.5 −12.5%) and NKX2–1 (12.5%) appear to occur with comparable frequencies in early- and advanced-stage tumors15, 34, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“earlier studies that identified a central role for WNT signaling in LUAD metastasis”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Analysis of mutations in PIK3CA and STK11, STK11 protein levels, and AMPK and AKT phosphorylation(33) led to the identification of three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by either STK11-inactivati…”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Cited by
Items 801–900 of 1,045
Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma
Pölönen, P., Deen, A. J., Leinonen, H. M., Jyrkkänen, H.-K., Linna-Kuosmanen, S., Mononen, M., Jain, A., Tuomainen, T., Pasonen‐Seppänen, S., Hartikainen, J. M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0956-6 · Cited by 94
Clinical applications of nanomedicines in lung cancer treatment
Norouzi, M., & Hardy, P. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.009 · Cited by 97
Mutation profile of non-small cell lung cancer revealed by next generation sequencing
Chang, Y., Tu, S.-J., Chen, Y., Liu, T., Lee, Y.-T., Yen, J.-C., Fang, H., & Chang, J. (2021) · Respiratory Research · doi:10.1186/s12931-020-01608-5 · Cited by 101
Multi-omics data integration by generative adversarial network
Ahmed, K. T., Sun, J., Cheng, S., Yong, J., & Zhang, W. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab608 · Cited by 88
Mazzone, P. J., Bach, P. B., Carey, J., Schonewolf, C. A., Bognar, K., Ahluwalia, M. S., Cruz-Correa, M. R., Gierada, D. S., Kotagiri, S., Lloyd, K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0519 · Cited by 100
“33, 34).”
ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis
Liu, J., Cho, S.-N., Akkanti, B. H., Jin, N., Mao, J., Long, W., Chen, T., Zhang, Y., Tang, X., Wistub, I. I., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.014 · Cited by 89
“[PubMed: 22761469] Cancer Genome Atlas Research Network (2012).”
BackgroundRADIA: RNA and DNA Integrated Analysis for Somatic Mutation Detection
Radenbaugh, A. J., Ma, S., Ewing, A., Stuart, J. M., Collisson, E. A., Zhu, J., & Haussler, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111516 · Cited by 89
Tao, Z., Blanc, J. M. L., Wang, C., Zhan, T., Zhuang, H., Wang, P., Yuan, Z., & Lü, B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0589 · Cited by 100
Sortilin limits EGFR signaling by promoting its internalization in lung cancer
Al‐Akhrass, H., Naves, T., Vincent, F., Magnaudeix, A., Durand, K., Bertin, F., Melloni, B., Jauberteau, M., & Lalloué, F. (2017) · Nature Communications · doi:10.1038/s41467-017-01172-5 · Cited by 94
Daemen, A., Liu, B., Song, K., Kwong, M., Gao, M., Hong, R., Nannini, M., Peterson, D., Liederer, B. M., de la Cruz, C., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.003 · Cited by 88
Integrated genetic and epigenetic analysis of myxofibrosarcoma
Ogura, K., Hosoda, F., Arai, Y., Nakamura, H. K., Hama, N., Totoki, Y., Yoshida, A., Nagai, M., Kato, M., Arakawa, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03891-9 · Cited by 99
Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers
Offin, M. D., Feldman, D., Ni, A., Myers, M. L., Lai, W. V., Pentsova, E. I., Boire, A. A., Daras, M., Jordan, E., Solit, D. B., et al. (2019) · Cancer · doi:10.1002/cncr.32461 · Cited by 100
Anusewicz, D., Orzechowska, M., & Bednarek, A. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-77284-8 · Cited by 108
SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
Wang, X., Zhang, H., Sapio, R. T., Yang, J., Wong, J., Zhang, X., Guo, J. Y., Pine, S. R., Remmen, H. V., Li, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22480-x · Cited by 101
KRAS G12C inhibitor combination therapies: current evidence and challenge
Miyashita, H., Kato, S., & Hong, D. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380584 · Cited by 85
Wang, D. Y. Q., Pham, N., Tong, J., Sakashita, S., Allo, G., Kim, L., Yanagawa, N., Raghavan, V., Wei, Y., To, C., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30472 · Cited by 93
Evidence of cancer‐promoting roles for AMPK and related kinases
Monteverde, T., Muthalagu, N., Port, J., & Murphy, D. J. (2015) · FEBS Journal · doi:10.1111/febs.13534 · Cited by 100
Alam, M. M., Lal, S., FitzGerald, K. E., & Li, Z. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0082-9 · Cited by 100
Shen, Q., Cheng, F., Song, H., Lü, W., Zhao, J., An, X., Liu, M., Chen, G., Zhao, Z., & Zhang, J. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.09.020 · Cited by 90
Lee, G. D., Lee, S. E., Oh, D., Yu, D.-B., Jeong, H. M., Kim, J., Hong, S., Jung, H. S., Oh, E., Song, J., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.031 · Cited by 93
“3% of lung adenocarcinomas in The Cancer Genome Atlas data set.(7) Small-molecule mesenchymal-epithelial transition (MET) tyrosine kinase inhibitors such as crizotinib and cabozantinib have shown remarkable initial responses in patients with lung adenocarcinoma harboring METex14 skipping.”
BackgroundCardnell, R. J., Li, L., Sen, T., Bara, R. O., Tong, P., Fujimoto, J., Ireland, A. S., Guthrie, M. R., Bheddah, S., Banerjee, U., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20621 · Cited by 93
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Hasako, S., Terasaka, M., Abe, N., Uno, T., Ohsawa, H., Hashimoto, A., Fujita, R., Tanaka, K., Okayama, T., Wadhwa, R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1206 · Cited by 88
Bahcall, M., Awad, M. M., Sholl, L. M., Wilson, F. H., Xu, M., Wang, S., Palakurthi, S. S., Choi, J., Ivanova, E. V., Leonardi, G. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0876 · Cited by 98
Prevalence and role of HER2 mutations in cancer
Cocco, E., Lopez, S., Santin, A. D., & Scaltriti, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.010 · Cited by 92
Capmatinib for the treatment of non-small cell lung cancer
Vansteenkiste, J., de Kerkhove, C. V., Wauters, E., & Mol, P. V. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1643239 · Cited by 99
“NRF2 addiction” in lung cancer cells and its impact on cancer therapy
Hammad, A., Namani, A., Elshaer, M., Wang, X. J., & Tang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.09.016 · Cited by 91
Evolving concepts of tumor heterogeneity
Zellmer, V. R., & Zhang, S. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-69 · Cited by 104
Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome
Marziali, G., Signore, M., Buccarelli, M., Grande, S., Palma, A., Biffoni, M., Rosi, A., D’Alessandris, Q. G., Martini, M., Larocca, L. M., et al. (2016) · Scientific Reports · doi:10.1038/srep21557 · Cited by 94
Jung, S., Kim, M. S., Jung, C. K., Park, H.-C., Kim, S. Y., Liu, J., Bae, J. S., Lee, S. H., Kim, T., Lee, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11922 · Cited by 90
Alam, H., Li, N., Dhar, S. S., Wu, S. J., Lv, J., Chen, K., Flores, E. R., Baseler, L. J., & Lee, M. G. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3571 · Cited by 99
Canale, M., Andrikou, K., Priano, I., Cravero, P., Pasini, L., Urbini, M., Delmonte, A., Crinò, L., Bronte, G., & Ulivi, P. (2022) · Cancers · doi:10.3390/cancers14051143 · Cited by 108
PROTAC therapy as a new targeted therapy for lung cancer
Li, J. W., Zheng, G., Kaye, F. J., & Wu, L. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.011 · Cited by 87
Receptor tyrosine kinases: biological functions and anticancer targeted therapy
Zhang, N., & Li, Y. (2023) · MedComm · doi:10.1002/mco2.446 · Cited by 113
Wolf, J., Hochmair, M. J., Han, J., Reguart, N., Souquet, P.-J., Smit, E. F., Orlov, S., Vansteenkiste, J., Nishio, M., de Jonge, M. J. A., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00441-8 · Cited by 87
Modulation of NF-κB/miR-21/PTEN Pathway Sensitizes Non-Small Cell Lung Cancer to Cisplatin
Yang, Z., Fang, S., Di, Y., Ying, W., Tan, Y., & Gu, W. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121547 · Cited by 87
GOLPH3 Links the Golgi, DNA Damage, and Cancer
Buschman, M. D., Rahajeng, J., & Field, S. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3081 · Cited by 87
Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer
Pécuchet, N., Laurent-Puig, P., Mansuet-Lupo, A., Legras, A., Alifano, M., Pallier, K., Didelot, A., Gibault, L., Danel, C., Just, P.-A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.6379 · Cited by 87
Lococo, F., Gandolfi, G., Rossi, G., Pinto, C., Rapicetta, C., Cavazza, A., Cesario, A., Galeone, C., Paci, M., & Ciarrocchi, A. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.020 · Cited by 87
Epigenetic silencing of miR-145-5p contributes to brain metastasis
Donzelli, S., Mori, F., Bellissimo, T., Sacconi, A., Casini, B., Frixa, T., Roscilli, G., Aurisicchio, L., Facciolo, F., Pompili, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5930 · Cited by 86
Stevens, L. E., Cheung, W. K. C., Adua, S. J., Estape, A. A., Zhao, M., Liu, Z. Z., Brewer, K. K., Herbst, R. S., & Nguyen, D. X. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1978 · Cited by 94
Emerging biomarkers for immune checkpoint inhibition in lung cancer
Cyriac, G., & Gandhi, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.006 · Cited by 89
Wang, C., Gu, Y., Zhang, E., Zhang, K., Qin, N., Dai, J., Zhu, M., Liu, J., Xie, K., Jiang, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0548-x · Cited by 87
Wang, S., Zhang, J., He, Z., Wu, K., & Liu, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32327 · Cited by 92
Goeman, F., Nicola, F. D., Scalera, S., Sperati, F., Gallo, E., Ciuffreda, L., Pallocca, M., Pizzuti, L., Krasniqi, E., Barchiesi, G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.003 · Cited by 90
Lu, L., Liu, L., Zhao, Q., Gui, R., & Zhao, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675545 · Cited by 105
Chen, F., Zhang, Y., Gibbons, D. L., Deneen, B., Kwiatkowski, D. J., Ittmann, M., & Creighton, C. J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3378 · Cited by 92
Pleural Effusion Aspirate for Use in 3D Lung Cancer Modeling and Chemotherapy Screening
Mazzocchi, A., Devarasetty, M., Herberg, S., Petty, W. J., Marini, F., Miller, L., Kucera, G., Dukes, D. K., Ruiz, J., Skardal, A., et al. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01356 · Cited by 82
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
Shire, N. J., Klein, A. B., Golozar, A., Collins, J. M., Fraeman, K. H., Nordstrom, B. L., McEwen, R., Hembrough, T., & Rizvi, N. A. (2020) · PLOS ONE · doi:10.1371/journal.pone.0238358 · Cited by 85
Wu, Y.-L. L. C., Soo, R. A., Locatelli, G., Stammberger, U. M., Scagliotti, G. V., & Park, K. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.003 · Cited by 84
Shahabi, S., Kumaran, V., Castillo, J., Cong, Z., Nandagopal, G., Mullen, D. J., Alvarado, A., Correa, M. R., Saizan, A., Goel, R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2034 · Cited by 86
Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis
Zhu, M., Huang, Y., Bender, M. E., Girard, L., Kollipara, R. K., Eglenen-Polat, B., Naito, Y., Savage, T. K., Huffman, K. E., Koyama, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2808 · Cited by 87
Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6
Park, E., Kim, N., Ficarro, S. B., Zhang, Y., Lee, B. I., Cho, A., Kim, K., Park, A. K.-J., Park, W., Murray, B. A., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3074 · Cited by 89
Inflammation as a driver and vulnerability of KRAS mediated oncogenesis
Kitajima, S., Thummalapalli, R., & Barbie, D. A. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.009 · Cited by 84
Oncogene-Driven Metabolic Alterations in Cancer
Min, H., & Lee, H. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.211 · Cited by 92
RB constrains lineage fidelity and multiple stages of tumour progression and metastasis
Walter, D. M., Yates, T. J., Ruiz-Torres, M., Kim-Kiselak, C., Gudiel, A. A., Deshpande, C., Wang, W. Z., Cicchini, M., Stokes, K. L., Tobias, J. W., et al. (2019) · Nature · doi:10.1038/s41586-019-1172-9 · Cited by 84
Leung, K. K., Wilson, G. M., Kirkemo, L. L., Riley, N. M., Coon, J. J., & Wells, J. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917947117 · Cited by 83
Liu, L., Liu, J., Шао, Д., Deng, Q., Tang, H., Zu, L., Chen, X., Guo, F., Lin, Y., Mao, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13410 · Cited by 90
The force of HER2 – A druggable target in NSCLC?
Jebbink, M., Langen, A. J. D., Boelens, M. C., Monkhorst, K., & Smit, E. F. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101996 · Cited by 87
Shaurova, T., Zhang, L., Goodrich, D. W., & Hershberger, P. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00281 · Cited by 89
“Sunitinib can irreversibly inhibit VEGFR family and is effective Frontiers in Genetics | www.frontiersin.org 9 March 2020 | Volume 11 | Article 281 in several solid tumors and pancreatic neuroendocrine tumors (Capozzi et al., 2016).”
BackgroundFan, Y., Liu, B., Chen, F., Song, Z., Han, B., Meng, Y., Hou, J., Cao, P., Chang, Y., & Tan, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.612144 · Cited by 94
Concepcion, C. P., Ma, S., LaFave, L. M., Bhutkar, A. J., Liu, M., DeAngelo, L. P., Kim, J. Y., Priore, I. S. D., Schoenfeld, A. J., Miller, M., et al. (2022) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 84
Boumelha, J., Trécesson, S. D. C., Law, E. K., Romero-Clavijo, P., Coelho, M. A., Ng, K. W., Mugarza, E., Moore, C., Rana, S., Caswell, D. R., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0325 · Cited by 86
“APOBEC3B expression increases during NSCLC progression(19) and has been associated with intra-tumoral heterogeneity (20,21).”
InfluentialMangiante, L., Alcala, N., Sexton‐Oates, A., Genova, A. D., González-Pérez, A., Khandekar, A., Bergstrom, E. N., Kim, J., Liu, X., Blázquez‐Encinas, R., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01321-1 · Cited by 103
Clinical and Molecular Characteristics of NF1 -Mutant Lung Cancer
Redig, A. J., Capelletti, M., Dahlberg, S. E., Sholl, L. M., Mach, S., Fontes, C., Shi, Y., Chalasani, P., & Jänne, P. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2377 · Cited by 84
Mulvaney, K. M., Matson, J. P., Siesser, P. F., Tamir, T. Y., Goldfarb, D., Jacobs, T. M., Cloer, E. W., Harrison, J. S., Vaziri, C., Cook, J. G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.729418 · Cited by 80
MET in human cancer: germline and somatic mutations
Tovar, E. A., & Graveel, C. R. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.64 · Cited by 83
MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Lu, X., Peled, N., Greer, J., Wu, W., Choi, P., Berger, A. H., Wong, S., Jen, K.-Y., Seo, Y., Hann, B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1944 · Cited by 84
Gasparini, P., Cascione, L., Landi, L. M., Carasi, S., Lovat, F., Tibaldi, C., Alì, G., D’Incecco, A., Minuti, G., Chella, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520329112 · Cited by 83
Synthetically lethal nanoparticles for treatment of endometrial cancer
Ebeid, K., Meng, X., Thiel, K. W., Do, A., Geary, S. M., Morris, A. S., Pham, E. L., Wongrakpanich, A., Chhonker, Y. S., Murry, D. J., et al. (2017) · Nature Nanotechnology · doi:10.1038/s41565-017-0009-7 · Cited by 86
The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
Öjlert, Å. K., Halvorsen, A. R., Nebdal, D. J. H., Lund‐Iversen, M., Solberg, S. K., Brustugun, O. T., Lingjærde, O. C., & Helland, Å. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12475 · Cited by 92
Koh, J., Kim, H. Y., Lee, Y., Park, I. K., Kang, C. H., Kim, Y. T., Kim, J.-E., Choi, M., Lee, W., Jeon, Y. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3458 · Cited by 86
Masood, A., Kancha, R. K., & Subramanian, J. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.08.004 · Cited by 89
Jiang, J., Zhang, J., Pang, Y., Bechmann, N., Li, M., Monteagudo, M., Calsina, B., Gimenez‐Roqueplo, A., Nölting, S., Beuschlein, F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa502 · Cited by 89
Robertson, H., Dinkova‐Kostova, A. T., & Hayes, J. D. (2020) · Cancers · doi:10.3390/cancers12123609 · Cited by 104
MS4A15 drives ferroptosis resistance through calcium-restricted lipid remodeling
Shan, X., Mueller, C., Pfeiffer, S., Kraft, V. A. N., Merl‐Pham, J., Bao, X., Feederle, R., Jin, X., Hauck, S. M., Schmitt‐Kopplin, P., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00883-z · Cited by 86
Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia
Wang, E., Pineda, J. M. B., Kim, W. J., Chen, S., Bourcier, J., Stahl, M. F., Hogg, S. J., Bewersdorf, J. P., Han, C., Singer, M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.002 · Cited by 97
Yang, Z., Jones, A., Widschwendter, M., & Teschendorff, A. E. (2015) · Genome biology · doi:10.1186/s13059-015-0699-9 · Cited by 92
Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer
Bennett, C. W., Berchem, G., Kim, Y. J., & El‐Khoury, V. (2016) · Oncotarget · doi:10.18632/oncotarget.11717 · Cited by 89
Matikas, A., Mistriotis, D., Georgoulias, V., & Kotsakis, A. P. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.12.005 · Cited by 88
Tanioka, M., Fan, C., Parker, J. S., Hoadley, K. A., Hu, Z., Yan, L., Hyslop, T., Pitcher, B. N., Soloway, M. G., Spears, P. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3431 · Cited by 79
Molecular impact of mutations in RNA splicing factors in cancer
Zhang, Q., Ai, Y., & Abdel-Wahab, O. I. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.07.019 · Cited by 97
RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma
Sakurai, T., Isogaya, K., Sakai, S., Morikawa, M., Morishita, Y., Ehata, S., Miyazono, K., & Koinuma, D. (2016) · Oncogene · doi:10.1038/onc.2016.35 · Cited by 83
Zhang, W. C., Wells, J. M., Chow, K.-H., Huang, H., Yuan, M., Saxena, T., Melnick, M. A., Politi, K. A., Asara, J. M., Costa, D. B., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0052-9 · Cited by 86
MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
Zheng, D., Wang, R., Ye, T., Yu, S., Hu, H., Shen, X., Li, Y., Ji, H., Sun, Y., & Chen, H. (2016) · Oncotarget · doi:10.18632/oncotarget.9541 · Cited by 80
Ma, Y., & Li, M. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-01856-4 · Cited by 84
Leonetti, A., Assaraf, Y. G., Veltsista, P. D., Hassouni, B. E., Tiseo, M., & Giovannetti, E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.002 · Cited by 84
Tumor diversity and the trade-off between universal cancer tasks
Hausser, J., Székely, P., Bar, N., Zimmer, A., Sheftel, H., Caldas, C., & Alon, U. (2019) · Nature Communications · doi:10.1038/s41467-019-13195-1 · Cited by 85
Salehi‐Rad, R., Li, R., Paul, M. K., Dubinett, S. M., & Liu, B. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.003 · Cited by 94
Molecular therapeutic targets in non-small cell lung cancer
Sankar, K. N., Gadgeel, S. M., & Qin, A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1787156 · Cited by 92
Takahashi, S., Asada, K., Takasawa, K., Shimoyama, R., Sakai, A., Bolatkan, A., Shinkai, N., Kobayashi, K., Komatsu, M., Kaneko, S., et al. (2020) · Biomolecules · doi:10.3390/biom10101460 · Cited by 81
A Performance Comparison of Commonly Used Assays to Detect RET Fusions
Yang, S., Aypar, U., Rosen, E. Y., Mata, D. A., Benayed, R., Mullaney, K. A., Jayakumaran, G., Zhang, Y., Frosina, D., Drilon, A. E. D. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3208 · Cited by 88
“The latter group was included given that RET fusions aremutually exclusive with oncogenic drivers in treatment-na€ ve lung cancers (7).”
BackgroundClinical application of a lung cancer organoid (tumoroid) culture system
Yokota, E., Iwai, M., Yukawa, T., Yoshida, M., Naomoto, Y., Haisa, M., Monobe, Y., Takigawa, N., Guo, M., Maeda, Y., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00166-3 · Cited by 91
Ras-Specific GTPase-Activating Proteins—Structures, Mechanisms, and Interactions
Scheffzek, K., & Shivalingaiah, G. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031500 · Cited by 79
Jorge, S. E., Schulman, S., Freed, J. A., VanderLaan, P. A., Rangachari, D., Kobayashi, S. S., Huberman, M. S., & Costa, D. B. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.028 · Cited by 81
In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis
Vaidyanathan, S., Cato, K., Tang, L., Pavey, S. J., Haass, N. K., Gabrielli, B. G., & Duijf, P. H. G. (2016) · Oncogene · doi:10.1038/onc.2016.94 · Cited by 83
Lee, J. W., Zhang, Y., Eoh, K. J., Sharma, R., Sanmamed, M. F., Wu, J., Choi, J., Park, H. S., Iwasaki, A., Kaftan, E., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.004 · Cited by 80
LncRNA H19 promotes lung cancer proliferation and metastasis by inhibiting miR-200a function
Zhao, Y., Feng, C., Li, Y., Ma, Y., & Cai, R. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03564-1 · Cited by 83
Jones, G. G., del Río, I. B., Sari, S., Sekerim, A., Young, L. C., Hartig, N., Areso Zubiaur, I., El-Bahrawy, M. A., Hynds, R. E., Lei, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10367-x · Cited by 80
Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers
Chen, R., Zhao, W., Fang, C., Yang, X., & Ji, M. (2020) · Journal of Cancer · doi:10.7150/jca.38391 · Cited by 89
Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC
Hellyer, J. A., Padda, S. K., Diehn, M., & Wakelee, H. A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.015 · Cited by 93
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-09
- Volume
- 511
- Issue
- 7511
- Pages
- 543-550
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4231481
- OpenAlex
- W2180481128
- Cited by
- 5,732
- References
- 42
- Citations by year
- 2026: 314 · 2025: 415 · 2024: 428 · 2023: 523 · 2022: 547 · 2021: 614 · 2020: 613 · 2019: 495 · 2018: 478 · 2017: 516 · 2016: 427 · 2015: 312 · 2014: 47
- FWCI
- 347.50
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-sa)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS (submittedVersion, cc-by-nc-sa)
- eSpace (Curtin University) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, R01HG006272)
- National Cancer Institute (U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24 CA137153, U24CA143845, U24CA126544, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA177558, P30CA008748, P30CA016672, P30CA006973)
- National Institute of General Medical Sciences (T32GM007753)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, RIT1, MGA, MYC amplification, EGFR mutation, RBM10, neurofibromatosis type 1, MET, ERBB2, MET exon 14 skipping, splicing alterations, MAPK signaling, PI3K signaling, DNA methylation, microRNA, transcriptome, proteome, molecular classification, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Female, Humans, Lung Neoplasms, Male, Mutation, Oncogenes, Sex Factors, Gene Expression Regulation, Neoplastic, Gene Dosage, Cell Cycle Proteins, Genomics, Molecular Typing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.